+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Critical Limb Ischemia Treatment Market By Treatment: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025

  • ID: 4854428
  • Report
  • July 2019
  • Region: Global
  • 120 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the global critical limb ischemia treatment market on a global and regional level. The study provides historical data for 2017 and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the global critical limb ischemia treatment market along with their impact on the demand over the forecast rime period. Additionally, the report includes the study of opportunities available in the global critical limb ischemia treatment market on a global level.

In order to give the users of this report a comprehensive view of the global critical limb ischemia treatment market. We have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the critical limb ischemia treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations, and joint ventures, research and development, and regional expansion of major participants involved in the critical limb ischemia treatment market on a global and regional basis.

The study provides a decisive view of the global critical limb ischemia treatment market that is bifurcated based on treatment and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some major players of the global critical limb ischemia treatment market are Boston Scientific Corporation, Medtronic, Cesca Therapeutics, Pluristem Therapeutics, Abbott Laboratories, Rexgenero, Micro Medical Solutions, LimFlow, and Cardiovascular Systems.

This report segments the global critical limb ischemia treatment market into:

Global Critical Limb Ischemia Treatment Market: Drug Type Analysis

  • Devices
  • Embolic Protection Devices
  • Peripheral Dilatation Systems
  • Balloon Dilators
  • Vascular stents
  • Medications
  • Antiplatelet Drugs
  • Antihypertensive Agents
  • Lipid-lowering Agents
  • Antithrombotic Agents
  • Others

Global Critical Limb Ischemia Treatment Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1.    Introduction
    • 1.1.    Report description and scope
    • 1.2.    Research scope 
    • 1.3.    Research methodology
      • 1.3.1.    Market research process
      • 1.3.2.    Market research methodology
  • Chapter 2.    Executive Summary
    • 2.1.    Global Critical Limb Ischemia Treatment market, 2017–2025 (USD Million)
    • 2.2.    Global Critical Limb Ischemia Treatment Market: Snapshot
  • Chapter 3.    Global Critical Limb Ischemia Treatment Market – Industry Dynamics
    • 3.1.    Introduction 
    • 3.2.    Market Drivers
      • 3.2.1.    Rising prevalence of Limb Ischemia
      • 3.2.2.    Increasing patient preference for devices
      • 3.2.3.    Introduction of newer agents 
    • 3.3.    Market Restraints
      • 3.3.1.    Competition from generic drugs
      • 3.3.2.    High cost of surgical treatment
    • 3.4.    Opportunities 
      • 3.4.1.    Promising pipeline and approvals 
    • 3.5.    Porter’s Five Forces Analysis 
    • 3.6.    Market Attractiveness Analysis
      • 3.6.1.    Market attractiveness analysis, by Treatment
      • 3.6.2.    Market attractiveness analysis, by region
  • Chapter 4.    Global Critical Limb Ischemia Treatment Market – Competitive Landscape
    • 4.1.    Company market share analysis
      • 4.1.1.    Global Critical Limb Ischemia Treatment Market: company market share, 2018
    • 4.2.    Strategic development
      • 4.2.1.    Acquisitions & mergers
      • 4.2.2.    New therapy launch
      • 4.2.3.    Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4.    Research and development and regional expansion
  • Chapter 5.    Global Critical Limb Ischemia Treatment Market – Treatment analysis
    • 5.1.    Global Critical Limb Ischemia Treatment Market: Treatment overview 
      • 5.1.1.    Global Critical Limb Ischemia Treatment Market Revenue share, by Treatment, 2018 and 2025
    • 5.2.    Devices
      • 5.2.1.    Global Critical Limb Ischemia Treatment market for Devices, 2017–2025 (USD Million)
    • 5.3.    Medication
      • 5.3.1.    Global Critical Limb Ischemia Treatment market for Medication, 2017–2025 (USD Million)
  • Chapter 6.    Global Critical Limb Ischemia Treatment Market – Regional Analysis
    • 6.1.    Global Critical Limb Ischemia Treatment Market: regional overview 
      • 6.1.1.    Global Critical Limb Ischemia Treatment Market Revenue share, by region, 2018 and 2025
    • 6.2.    North America
      • 6.2.1.    North America Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.2.2.    The U.S.
        • 6.2.2.1.    The U.S. Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million)
      • 6.2.3.    Canada 
        • 6.2.3.1.    Canada Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.3.    Europe 
      • 6.3.1.    Europe Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.3.2.    UK
        • 6.3.2.1.    UK Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.3.    Germany
        • 6.3.3.1.    Germany Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.4.    France
        • 6.3.4.1.    France Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.5.    Rest of Europe
        • 6.3.5.1.    Rest of Europe Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.4.    Asia Pacific 
      • 6.4.1.    Asia Pacific Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.4.2.    China
        • 6.4.2.1.    China Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.3.    Japan
        • 6.4.3.1.    Japan Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.4.    India
        • 6.4.4.1.    India Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.5.    Rest of Asia Pacific
        • 6.4.5.1.    Rest of Asia Pacific Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.5.    Latin America
      • 6.5.1.    Latin America Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.5.2.    Brazil
        • 6.5.2.1.    Brazil Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.5.3.    Rest of Latin America
        • 6.5.3.1.    Rest of Latin America Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.6.    The Middle East and Africa
      • 6.6.1.    The Middle East and Africa Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
  • Chapter 7.    Company Profile 
    • 7.1.    Boston Scientific Corporation
      • 7.1.1.    Overview  
      • 7.1.2.    Financials  
      • 7.1.3.    Treatment portfolio
      • 7.1.4.    Business strategy 
      • 7.1.5.    Recent developments 
    • 7.2.    Medtronic
      • 7.2.1.    Overview  
      • 7.2.2.    Financials  
      • 7.2.3.    Treatment portfolio
      • 7.2.4.    Business strategy 
      • 7.2.5.    Recent developments 
    • 7.3.    Cesca Therapeutics
      • 7.3.1.    Overview  
      • 7.3.2.    Financials  
      • 7.3.3.    Treatment portfolio
      • 7.3.4.    Business strategy 
      • 7.3.5.    Recent developments 
    • 7.4.    Pluristem Therapeutics
      • 7.4.1.    Overview  
      • 7.4.2.    Financials  
      • 7.4.3.    Treatment portfolio
      • 7.4.4.    Business strategy 
      • 7.4.5.    Recent developments 
    • 7.5.    Abbott Laboratories
      • 7.5.1.    Overview  
      • 7.5.2.    Financials  
      • 7.5.3.    Treatment portfolio
      • 7.5.4.    Business strategy 
      • 7.5.5.    Recent developments 
    • 7.6.    Rexgenero
      • 7.6.1.    Overview  
      • 7.6.2.    Financials  
      • 7.6.3.    Treatment portfolio
      • 7.6.4.    Business strategy 
      • 7.6.5.    Recent developments 
    • 7.7.    Micro Medical Solutions
      • 7.7.1.    Overview  
      • 7.7.2.    Financials  
      • 7.7.3.    Treatment portfolio
      • 7.7.4.    Business strategy 
      • 7.7.5.    Recent developments 
    • 7.8.    LimFlow
      • 7.8.1.    Overview  
      • 7.8.2.    Financials  
      • 7.8.3.    Treatment portfolio
      • 7.8.4.    Business strategy 
      • 7.8.5.    Recent developments
    • 7.9.    Cardiovascular Systems
      • 7.9.1.    Overview  
      • 7.9.2.    Financials  
      • 7.9.3.    Treatment portfolio
      • 7.9.4.    Business strategy 
      • 7.9.5.    Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll